paclitaxel cationic liposomes

Phase 1Small molecule

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

paclitaxel cationic liposomes is one of 90 small molecule programs targeting Patients With Advanced Solid Tumors. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Patients With Advanced Solid TumorsRecruiting

First-Line TreatmentRecruiting

Patients With Advanced Solid TumorsPhase 1

Recruiting

First-Line TreatmentPhase 1

Recruiting

Competition

Competitive Landscape

225 competitors in Patients With Advanced Solid Tumors

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 2

25 2

Keytruda

Merck & Co.

Phase 2

19 3

Avastin

Roche

Phase 2

10 4

Lynparza

AstraZeneca

Phase 2

4 5

Tecentriq

Roche

Phase 2

4 6

Camptosar

Pfizer

Phase 2

4 7

Beyfortus

BeiGene

Phase 2

3 8

Ibrance

Pfizer

Phase 2

2 9

Adriamycin

Pfizer

Phase 2

1 10

Erbitux

IImclone

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Patients With Advanced Solid Tumors

NCT06632574

Clinical

Trials by Indication[1]

First-line Treatment1 trial

Paclitaxel Cationic Liposome (Hepatic Arterial Infusion) in Combination With Systemic Therapy as First-Line Treatment in Colorectal Liver Metastases

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT07117435·7 enrolled

Patients With Advanced Solid Tumors1 trial

A Clinical Study of Paclitaxel Cationic Liposomes for the Treatment of Patients With Advanced Solid Tumors

Recruiting· CSPC ZhongQi Pharmaceutical Technology Co., Ltd. logo

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·Phase 1·NCT06632574·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for paclitaxel cationic liposomes. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — paclitaxel cationic liposomes compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for paclitaxel cationic liposomes. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — CSPC ZhongQi Pharmaceutical Technology Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

paclitaxel cationic liposomes

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

First-line Treatment1 trial

Patients With Advanced Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News